Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Ipsen details growing pains as teens transition to adult care
An Ipsen-commissioned survey has
508 words~2 min read
Related reading
Pharma urged to modernize patient support as young adult cancer rates rise
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to…
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal;…
As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to cur | As China-developed…
Cancer is changing. Is pharma marketing changing with it?
Early-onset cancers are rising among adults 18–49, reshaping how patients are diagnosed, supported, and engaged. This report…
Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting…
Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting to…
How trusted research data enables smarter decisions in life sciences
Learn how high-quality, standardized research data, full-text content, and AI-powered technologies can help life sciences teams…
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s…
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…